EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)Business Wire • 08/12/26
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ExelixisPRNewsWire • 08/11/26
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)PRNewsWire • 08/10/26
EXEL Tops Q2 Earnings Estimates, Misses on Sales, Lowers '26 ViewZacks Investment Research • 08/06/26
Exelixis (EXEL) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/06/26
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate UpdateBusiness Wire • 08/05/26
These 3 Healthcare Stocks Have Crushed the Market This Year. Here's Why There's More Upside AheadThe Motley Fool • 07/24/26
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026Business Wire • 07/22/26
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 07/16/26
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?Zacks Investment Research • 07/09/26
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal CancerBusiness Wire • 06/22/26
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/09/26
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/04/26
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/03/26